Friedrich von Bohlen und Halbach
German (born 1962), has been a Board Member of Cosmo Pharmaceuticals NV since 2006 elected on the list proposed by the investors.
Friedrich von Bohlen is managing partner at dievini Hopp BioTech Holding GmbH & Co. KG., the company managing the life science activities and investments of Dietmar Hopp.
He is a member of the following boards: chairman of the board of Molecular Health AG, Basel, chairman of the board (Beirat) of Apogenix GmbH, Heidelberg, chairman of the board (Beirat) of CureVac GmbH, Tübingen, member of the board (Beirat) of Cytonet GmbH & Co. KG, Weinheim, member of the board (Beirat) of febit Holding GmbH, Heidelberg, member of the board (Beirat) of Immatics GmbH, Tübingen, member of the board of Agennix AG, Heidelberg, and member of the board of Wilex AG, Munich.
Friedrich von Bohlen has more than 15 years of entrepreneurial experience in the Life Sciences. As former CEO of Lion Bioscience AG he led Lion’s IPO in 2000 at “Neuer Markt,” Frankfurt, and at NASDAQ, New York. In addition to that, he has been awarded numerous prizes, including the German Entrepreneur of the Year prize in 1999 by Ernst & Young, SAP and “Manager Magazin.” Friedrich von Bohlen holds a diploma in biochemistry from the University of Zurich and a PhD in neurobiology from the Swiss Federal Institute of Technology (ETH) in Zurich.
None of the unrelated companies that Friedrich von Bohlen und Halbach is a major shareholder of or is on the board of had any business activities with the Company.